MTTI is a clinical stage company transforming the lives of patients burdened with severe and life-threatening diseases.
MTTI’s medicine advancing selective radiotherapeutics, EBTATE targeting neuroendocrine tumors.
MTTI’s team seasoned executives from multinational pharmaceutical companies, each with a successful track record.
As Nukleon, we serve as the exclusive distributor of MTTI in the Turkish market.
For more information, you can visit the link www.mtarget.com